DermBiont Acquires SeylanMED to Expand Dermatology Pipeline

Eilean Therapeutics Acquires Ness Therapeutics

March 4, 2024

Biotechnology

Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.

Nextmune Acquires VetBiotek

December 22, 2023

Veterinary

Nextmune, a global specialty animal-health company, acquired VetBiotek, a developer of veterinary dermatology topical formulations including MicroSilver BG and Ceramide III products. The acquisition expands Nextmune’s dermatology portfolio and aims to improve production, packaging, distribution and access of VetBiotek’s products to veterinary clinics and distributors.

Galderma Acquires ALASTIN Skincare

January 5, 2022

Healthcare Services

Galderma has completed the acquisition of ALASTIN Skincare, Inc., receiving U.S. antitrust clearance and closing the deal announced November 29, 2021. The purchase adds ALASTIN's physician-dispensed aesthetic skincare portfolio, including its patented TriHex Technology, to Galderma's integrated dermatology platform to expand product capabilities and better serve aesthetic professionals and consumers.

NovaBay Pharmaceuticals Acquires DERMAdoctor

September 28, 2021

Consumer Products

NovaBay Pharmaceuticals, Inc. has entered into a definitive agreement to acquire DERMAdoctor, LLC for $15.0 million ( $12.0 million cash at closing plus up to $3.0 million in earnouts). The deal brings DERMAdoctor's ~30-product skincare portfolio and its 13-person team (co-founders Audrey and Jeff Kunin to remain) into NovaBay's commercial platform to expand its presence in the U.S. beauty market and capture revenue and operating synergies.

Mountaingate Capital Acquires BioDerm

January 11, 2021

Medical Devices

Denver-based private equity firm Mountaingate Capital has acquired BioDerm, Inc., a Largo, Florida manufacturer of disposable medical devices and wound care supplies, in a transaction supported by subordinated debt and an equity co-investment from Five Points Capital and additional financing from Abacus Finance Group. Mountaingate said it will accelerate BioDerm's organic growth and pursue add-on acquisitions to expand product and service offerings while management and founder shareholders retain a continued ownership/board role.

Eli Lilly Acquires Dermira for $1.1 Billion

January 10, 2020

Biotechnology

Eli Lilly agreed to acquire Dermira, Inc. in an all-cash transaction valued at approximately $1.1 billion ($18.75 per share). The deal adds Dermira's Phase 3 IL-13 antibody candidate lebrikizumab and marketed dermatology product QBREXZA to Lilly's immunology and dermatology portfolio and is expected to close in Q1 2020.